RADX — Radiopharm Theranostics Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1949257 ·
Australia
Last close
$0.67
Market Cap
$9.70M
52W High
$16.25
52W Low
$0.65
ADV30
50,299
Next earnings
—
No quarterly fundamentals indexed for this ticker.
Balance + Analyst (yfinance extras)
Retained Earnings
—
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$13,502,270
EBITDA
$-49,613,928
Free Cash Flow
$-30,744,724
Enterprise Value
$16,890,226
Total Cash
$4,138,074
Total Debt
$0
Shares Out
14,458,498
Trailing EPS
$-3.88
Book Value
$1.51
ROE
-174.7%
ROA
-44.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 2,767,888 | -58,223,929 | -56,950,494 | 60,133,579 | 37,809,896 | 24,687,209 | — |
| Jun 2025 | 3,633,422 | -34,640,735 | -38,342,457 | 86,481,876 | 43,609,972 | 44,792,004 | — |
| Jun 2024 | 299,228 | -37,173,885 | -47,949,119 | 72,036,345 | 44,683,059 | 28,122,562 | — |
| Jun 2023 | 292,359 | -31,690,601 | -34,611,194 | 74,949,668 | 29,370,243 | 44,384,488 | — |
| Jun 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.32
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BIVI | BIOVIE INC. | $9.61M | $1.00 | — |
| PBM | PSYENCE BIOMEDICAL LTD. | $9.57M | $2.51 | — |
| PTN | PALATIN TECHNOLOGIES INC | $9.55M | $5.36 | — |
| GDTC | CytoMed Therapeutics Ltd | $9.27M | $0.78 | — |
| CLRB | Cellectar Biosciences, Inc. | $9.24M | $0.92 | — |
News headlines (Yahoo Finance, 1h cache)
Radiopharm Theranostics Presents Interim Analysis from Phase 2b Imaging Study of RAD101 in Suspected Recurrent Brain Metastases Following Radiotherapy at the Society for Neuro-Oncology Annual Meeting
2026-11-16 13:00 · Yahoo
Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases
2026-11-04 12:00 · Yahoo
Radiopharm Theranostics Reports Business Update
2026-11-02 13:00 · Yahoo
Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
2026-10-05 12:00 · Yahoo
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
2026-09-09 11:00 · Yahoo
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
2026-08-26 11:00 · Yahoo
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
2026-08-20 11:00 · Yahoo
Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
2026-08-17 11:30 · Yahoo
RADX: RAD101 Topline & FY:26 Cash Flows
2026-08-03 15:14 · Yahoo
UPDATE – International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 12, 2026
2026-11-09 16:56 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.